Astellas sold Zephama, operating in the over-the-counter drug business, to Daiichi Sankyo Co., Ltd. in Japan to concentrate Astellas' managerial resources on its ethical drug business.
Astellas launched Geninax®, an oral new-type quinololone antibacterial agent, in Japan.
Astellas acquired Agensys, Inc., a biotechnology company specialized in therapeutic antibody research and development in cancer in the U.S.
Astellas acquired OSI Pharmaceuticals, Inc., a biotechnology company in the U.S. to create an oncology platform.
Astellas launched Betanis® in Japan for the treatment of overactive bladder (OAB).
Astellas signed United Nations Global Compact.
Astellas launched a wind turbine power generation station and a woodchip biomass boiler in the Kerry Plant in Ireland.
Astellas participated in the new public-private partnership to develop a treatment for schistosomiasis-infected preschool children.
Astellas launched XTANDI® in the U.S. for the treatment of metastatic castration-resistant prostate cancer.
Astellas launched Gonax® in Japan for the treatment of prostate cancer.
Astellas entered collaborative new drug discovery research with the National Institute of Advanced Industrial Science and Technology (AIST) for neglected tropical diseases caused by protozoan parasites.
Astellas launched MYRBETRIQ® in the U.S. for the treatment of OAB.
Astellas and UCB Japan launched Cimzia® in Japan for the treatment of adult patients with rheumatoid arthritis.
Astellas announced participation in Global Health Innovative Technology Fund (GHIT Fund).
Astellas and Amgen concluded an agreement for established alliance innovative joint venture, Astellas Amgen Biopharma in Japan.
Astellas launched Suglat® in Japan for the treatment of type 2 diabetes.
Astellas funded a €1.5 million groundbreaking programme to tackle obstetric fistula in Kenya.
Astellas launched XTANDI® in Japan for the treatment of prostate cancer.
Astellas acquired Ocata Therapeutics, Inc., a biotechnology company in the U.S. to enable Astellas to establish a presence in ophthalmology and a leading position in cell theapy.
Astellas launched Repatha® in Japan for the treatment of high cholesterol.
Astellas and World Anti-Doping Agency announced global initiative to prevent misuse and abuse of medicines for doping in sports.
Astellas acquired Ganymed Pharmaceticals AG, a biopharmaceutical company, in Germany to further expand Astellas' oncology presence by adding anti-body program, zolbetuximab.
Astellas participated in Access Accelerated, a global initiative aimed at improving access to non-communicable diseases prevention, diagonosis and treatment.
Astellas launched LINZESS® in Japan for the treatment of irritable bowel syndrome with conspitation.
Astellas acquired Ogeda SA, a drug discovery company, in Belgium to expand Astellas' pipeline by adding a selective NK3 receptor atagonist, fezolinetant.
Astellas entered into a new collaborative research agreement with TB Alliance to discover anti-tuberculosis drugs.
Astellas entered into a screening collaboration agreement with Medicines for Malaria Venbure to discover antimalarial drugs.
Astellas acquired Mitobridge, Inc., a bio-venture company in the U.S. to accelerate Astellas' research and development in diseases associated with mitochondrial dysfunctions.
Astellas acquired Universal Cells, Inc., a bio-venture company which has ability to produce pluripotent stem cells that have lower immunological rejections.
Astellas participated in Neglected Tropical Diseases Drug Discovery Booster Consortium with DNDi and Seven Other Pharmaceutical Companies.
Astellas acquired Quethera, a gene theraphy company in the U.K. to further Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma.
Astellas launched Dafclir® in Japan for the treatment of infectious enteritis caused by Clostridium difficile.
Astellas and BANDAI NAMCO Entertainment Inc. concluded an agreement for joint development of application for smartphone exercise support application.
Science Based Targets Initiative approved Astellas’ greenhouse gas reduction plan.
Astellas launched BLINCYTO® in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Astellas launched the Astellas Global Health Foundation to support improving access to health for underserved populations.
Astellas launched XOSPATA® in Japan and the U.S. to provide a therapeutic option for the treatment of Acute Myeloid Leukemia.
Astellas acquired Potenza Therapeutics Inc. in the U.S. to add clinical stage novel immuno-oncology programs to Astellas' oncology pipeline.
Astellas launched EVENITY® in Japan for the treatment of osteoporosis.
Astellas launched Smyraf® in Japan for the treatment of rheumatoid arthritis in patients.
Astellas launched Evrenzo® in Japan for the treatment of renal anemia in patients on dialysis.
Astellas entered into strategic alliance for digital therapeutics with Welldoc, Inc., a digital health company.
Astellas acquired Xyphos Biosciences, Inc., a biotechnology company in the U.S. to accelerate next-generation cancer immunotherapy.
Astellas lauched PADCEV® in the U.S. for the treatment of urothelial cancer.
Astellas acquired Audentes Therapeutics, Inc., a biotechnology company in the U.S. to complement capabilities and resources of Astellas for creating an industry-leading gene therapy company.
Astellas acquired Nanna Therapeutics Limited, in the U.K. to accelerate Astellas' research in diseases associated with mitochondrial dysfunctions.
Astellas, City of Yokohama, and Yokohama City University developed science-based exercise programs through industry-government-academia collaboration.
Astellas launched science-based fitness service, Fit-eNce®.
Astellas acquired iota Biosciences, Inc. in the U.S. to explore new biosensing and treatment measures using ultra-small implantable medical devices.
Astellas supported recommendations of Task Force on Climate-related Financial Disclosures (TCFD).
Launch of New Products
Building a Platform to Support Growth
Optimization of Resource Allocation
Initiatives to Support Society and Company's Sustainable Growth